Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.

Margot, Nicolas A; Naik, Vidula; VanderVeen, Laurie; Anoshchenko, Olena; Singh, Renu; Dvory-Sobol, Hadas; Rhee, Martin S; Callebaut, Christian

Margot, Nicolas A; Naik, Vidula; VanderVeen, Laurie; Anoshchenko, Olena; Singh, Renu; Dvory-Sobol, Hadas; Rhee, Martin S; Callebaut, Christian.

Margot NA; Clinical Virology, Gilead Sciences, Inc, Foster City, California, USA.
Naik V; Clinical Virology, Gilead Sciences, Inc, Foster City, California, USA.
VanderVeen L; Clinical Virology, Gilead Sciences, Inc, Foster City, California, USA.
Anoshchenko O; Clinical Pharmacology, Gilead Sciences, Inc, Foster City, California, USA.
Singh R; Clinical Pharmacology, Gilead Sciences, Inc, Foster City, California, USA.
Dvory-Sobol H; Clinical Research, Gilead Sciences, Inc, Foster City, California, USA.
Rhee MS; Clinical Research, Gilead Sciences, Inc, Foster City, California, USA.
Callebaut C; Clinical Virology, Gilead Sciences, Inc, Foster City, California, USA.

J Infect Dis ; 226(11): 1985-1991, 2022 11 28.

Article en En | MEDLINE | ID: mdl-36082606

Asunto(s)

Fármacos Anti-VIH; Infecciones por VIH; VIH-1; Humanos; Farmacorresistencia Viral/genética; Cápside; Fármacos Anti-VIH/farmacología; Fármacos Anti-VIH/uso terapéutico; VIH-1/genética; Antirretrovirales/uso terapéutico

Palabras clave

HIV; capsid; lenacapavir; monotherapy; multidrug resistance; optimized background regimen

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Fármacos Anti-VIH Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google